Literature DB >> 1937747

Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

H L Collins1, G J Bancroft.   

Abstract

The encapsulated yeast Cryptococcus neoformans is a significant cause of opportunistic infection in patients with impaired cell-mediated immunity. The major virulence determinant of the organism is an antiphagocytic polysaccharide capsule synthesized after entry into the host. Using both an encapsulated virulent strain and an acapsular avirulent mutant, we have demonstrated the reduced ability of the encapsulated strain to stimulate specific T-cell responses in vitro. This reduction was mediated by the antiphagocytic action of the capsule rather than by direct inhibition of antigen processing and presentation, since prior opsonization with complement enhanced the ingestion of encapsulated yeast cells by purified antigen-presenting cells and allowed significant T-cell activation. Once ingestion had occurred, cryptococci were efficiently processed by activated macrophages via a chloroquine-sensitive pathway. Cryptococcal antigens were available for T-cell recognition within 1 to 2 h of interaction with macrophages and presented in a major histocompatibility complex-restricted manner. Our results suggest that the antiphagocytic action of the polysaccharide capsule is an important determinant for the development of T-cell immunity to C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1937747      PMCID: PMC258972          DOI: 10.1128/iai.59.11.3883-3888.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  Antigen presentation.

Authors:  E R Unanue; J C Cerottini
Journal:  FASEB J       Date:  1989-11       Impact factor: 5.191

2.  The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.

Authors:  R D Diamond; J E May; M A Kane; M M Frank; J E Bennett
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

3.  Cell-mediated immunity in Cryptococcosis.

Authors:  J R Graybill; R H Alford
Journal:  Cell Immunol       Date:  1974-10       Impact factor: 4.868

4.  Diagnosis of cryptococcal meningitis. Value of immunologic detection of cryptococcal antigen.

Authors:  J S Goodman; L Kaufman; M G Koenig
Journal:  N Engl J Med       Date:  1971-08-19       Impact factor: 91.245

5.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Delayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformans.

Authors:  R J Hay; E Reiss
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

7.  Cryptococcus neoformans IV. The Not-So-Encapsulated Yeast.

Authors:  F Farhi; G S Bulmer; J R Tacker
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

View more
  36 in total

1.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.

Authors:  S M Levitz; T S Harrison; A Tabuni; X Liu
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans.

Authors:  Tiffany Guess; Hoyin Lai; Serenah E Smith; Linda Sircy; Kirsten Cunningham; David E Nelson; Erin E McClelland
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

5.  Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.

Authors:  E Blasi; R Mazzolla; R Barluzzi; P Mosci; F Bistoni
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.

Authors:  M S Alcouloumre; M A Ghannoum; A S Ibrahim; M E Selsted; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 8.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans.

Authors:  E Blasi; R Barluzzi; R Mazzolla; F Bistoni
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.